Acinetobacter baumannii is undoubtedly one of the most successful pathogens responsible
for hospital-acquired nosocomial infections in the modern healthcare system. Due to the …

Acinetobacter baumannii (named in honor of the American bacteriologists Paul and Linda
Baumann) is a Gram-negative, multidrug-resistant (MDR) pathogen that causes nosocomial …

Colistin is the last resort for treatment of multidrug-resistant Acinetobacter baumannii.
Unfortunately, resistance to colistin has been reported all over the world. The highest …

During the past few decades Acinetobacter baumannii has evolved from being a commensal
dweller of health-care facilities to constitute one of the most annoying pathogens …

'Old'colistin and polymyxin B are increasingly used as last-line therapy against multidrug-
resistant Gram-negative bacteria Pseudomonas aeruginosa, Acinetobacter baumannii, and …

In order to provide preliminary guidance for rational antibiotic combination therapy in the
clinic, a systematic review and meta-analysis was performed to evaluate the in vitro …

In this study we aimed to assess the safety and efficacy of high-dose IV colistin (COL) and
aerosolized COL for the treatment of Acinetobacter baumannii ventilator-associated …

Antimicrobial resistance is a major global health challenge. As few new efficacious
antibiotics will become available in the near future, peptide antibiotics continue to be major …

Objectives Combination therapy is recommended for the treatment of KPC-producing
Klebsiella pneumoniae (KPC-Kp), but the optimal regimen for colistin-resistant strains is …

Resistance to minocycline has emerged in multidrug-resistant Acinetobacter baumannii
isolates from Buenos Aires hospitals. Few reports about the description and dispersion of tet …